Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab

Pfizer (PFE) announced that the European Commission (EC) approved the label expansion of its 20-valent pneumococcal conjugate vaccine for use in infants, children and adolescents aged six weeks through 17 years of age.Following this decision, infants and children aged under 18 years can now be immunized with the Pfizer vaccine for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae (S. pneumoniae).A pneumococcal infection is caused by the bacterium S. pneu ...